Background Pharmacists working in community and primary care are increasingly developing advanced skills to provide enhanced services, particularly in dealing with minor acute illness. These services can potentially free-up primary care physicians' time; however, it is not clear whether they are sufficiently cost effective to be recommended for wider provision in the UK. Objective The aim of this study was to review published economic evaluations of enhanced pharmacy services in the community and primary care settings. Methods We undertook a systematic review of economic evaluations of enhanced pharmacy services to inform NICE guidelines for emergency and acute care. The review protocol was developed and agreed with the guideline committee. The National Health Service Economic Evaluation Database, Health Technology Assessment Database, Health Economic Evaluations Database, MEDLINE and EMBASE were searched in December 2016 and the search was updated in March 2018. Studies were assessed for applicability and methodological quality using the NICE Economic Evaluation Checklist. Results Of 3124 records, 13 studies published in 14 papers were included. The studies were conducted in the UK, Spain, The Netherlands, Australia, Italy and Canada. Settings included community pharmacies, primary care/general practice surgeries and patients' homes. Most of the studies were assessed as partially applicable with potentially serious limitations. Services provided in community and primary care settings were found to be either dominant or cost effective, at a £20,000 per quality-adjusted life-year threshold, compared with usual care. Those delivered in the patient's home were not found to be cost effective. Conclusions Advanced pharmacy services appear to be cost effective when delivered in community and primary care settings, but not in domiciliary settings. Expansion in the provision of these services in community and primary care can be recommended for wider implementation.
Introduction
Pharmacists are highly trained health care professionals, qualified to give advice on health issues and medicines, and also to ensure the safe supply and use of medicines by the public [1] . For decades, the role of pharmacists in the community has involved dispensing and supply of prescriptions issued by doctors; however, in recent years the role and locations from which pharmacists in the community work have evolved and pharmacists have been undertaking more clinical roles, such as prescribing, in addition to the traditional dispensing services [2] . This provides an opportunity to help health systems challenged by the combined demand for primary care services and limited supply of primary care physicians [3] by reducing unnecessary visits to family doctors and emergency departments for minor acute illness that would otherwise impact adversely on the quality of patient care [4] . It also strengthens the ability of primary care services to deliver on its critical role outlined in the World Health Organization (WHO) Astana Declaration, which aims to ensure that the highest standard of health is attained everywhere around the world [5] .
Recent data in the UK have shown a reduction in the number of full-time equivalent positions for family doctors
Key Points for Decision Makers
There is strong economic evidence to suggest that for people with or at risk of acute illness and medical emergencies, community pharmacy-based enhanced services are cost effective. Commissioning these services should be provided.
Inclusion of clinically trained pharmacists in general practice teams is supported by the economic evidence and should be considered by commissioners.
Pharmacist interventions delivered in people's own homes are not cost effective, based on the published evidence. Thus, commissioning these services should only be considered for logistical or clinical reasons on an individual case-by-case basis, taking patients' health and mobility needs into account. patient education. Most studies either recruited patients who had a single long-term condition requiring multiple medications, or a heterogeneous population with polypharmacy. Several of the latter studies only included older people. The findings of this review indicated a clear benefit in terms of patient outcomes for interventions delivered by pharmacists at community pharmacies, with mixed results regarding the effectiveness of services provided by pharmacists in other primary care settings [59] .
A unique feature of NICE guidelines is the consideration of cost effectiveness alongside the clinical effectiveness evidence. Thus, this systematic review was undertaken to identify and assess the quality and applicability of the published economic evaluations of enhanced services provided by community-based pharmacists. The threshold used to determine cost effectiveness was £20,000 per qualityadjusted life-year (QALY) gained.
Methods
In accordance with NICE methodology, the review question was developed in consultation with stakeholder groups and then refined by the Guideline Committee using the PICO (population, intervention, comparison and outcome) framework for intervention reviews to guide the literature searching process, critical appraisal and evidence synthesis [60] .
Systematic literature searches were undertaken to identify health economic evidence within published literature relevant to the review question. The searches were conducted in the NHS Economic Evaluation Database (NHS EED), the Health Technology Assessment Database (HTA) and the Health Economic Evaluations Database (HEED) (NHS EED ceased to be updated after March 2015; HEED was used for searches up to December 2014 but subsequently ceased to be available). Additionally, searches were run on MEDLINE and EMBASE using a health economic evaluation filter. Where possible, searches were restricted to papers published in English; studies published in languages other than English were not reviewed. Initial searches were run up to December 2016 and then updated on 23 March 2018. No paper published after this date was considered. The search strategies are included in Online Resource 1.
Study selection was undertaken first by one of the authors (DD) sifting through the titles and abstracts of the retrieved records in accordance with the inclusion/exclusion criteria (listed below) and then being independently checked by another author (AH). Differences in opinion were resolved through discussions among the two authors. If a consensus was not reached, the opinion of a more senior health economist (DW) was sought and the decision discussed with the community pharmacy expert on the committee (MV), the guideline committee chair (JB) and the deputy chair (PD).
[general practitioners (GPs)] and this has resulted in an imbalance such that the number of GPs cannot keep up with the demand for services [6] . In response, the 'next steps' review of the National Health Service (NHS) Five Year Forward View has proposed employing clinical pharmacists in patient-facing roles as one strategy to fill this skill shortage gap and address patients' unmet needs through the provision of novel services such as minor ailment schemes, new medicines services (NMS) [7] , and medication use reviews (MURs) [8] . This has been further emphasised in the NHS Long Term Plan, which stressed the importance of pharmacists' roles and their contribution [9] . However, funding for community pharmacy in the UK has recently been drastically cut, leading to concerns about the sustainability of providing these enhanced services and the need to evaluate whether these services are value for money in a resourcelimited health system [10] .
In 2014, the National Institute for Health and Care Excellence (NICE) commissioned the development of a guideline for the delivery of acute and medical emergency care services in the English NHS. Priority areas were defined in a stakeholder meeting representing 70 national organisations, including patient groups. Assessing the effectiveness of pharmacist interventions delivered in community settings was one of the priorities, with the aim of developing recommendations regarding wider use of these services across the NHS. A systematic review of published studies assessing the clinical effectiveness and safety of community-based pharmacist interventions was undertaken as part of the guideline. This identified and included 37 randomised controlled trials (RCTs) published in 48 papers that assessed the effectiveness of these services . In the majority of these studies, the services included some type of medication review and
Inclusion/Exclusion Criteria
The key population inclusion criterion was:
• adults (18 years of age and over) and young people (16- 17 years of age) who are at risk of, and those who seek or are referred for, emergency NHS care for a suspected or confirmed acute illness, including medical emergencies.
The key population exclusion criteria were:
• children • people with acute obstetric emergencies • people with acute mental health emergencies, once a diagnosis had been made • people with acute surgical emergencies, once a diagnosis had been made • people who had experienced major trauma, complex or non-complex fractures or spinal injury • people in hospital who were not there for an acute medical emergency (i.e. elective admissions) and who did not develop an acute medical emergency during their stay • people already in hospital with acute deterioration • people with chronic conditions who were being managed as outpatients but who required an elective admission for treatment from specialists involved in the acute pathway.
The key study inclusion criterion was that the study had to be a full economic evaluation (studies comparing costs and health consequences of alternative courses of action: cost-utility, cost-effectiveness, cost-benefit and cost-consequences analyses). Comparative costing studies that addressed the review question in the relevant population were also considered for inclusion.
Studies that only reported cost per hospital (not per patient), or only reported average cost effectiveness without disaggregated costs and effects, were excluded, as were literature reviews, conference abstracts, posters, letters, editorials, comment articles and unpublished studies. Studies published before 2005 and studies from non-OECD (Organisation for Economic Co-operation and Development) countries or the US were also excluded on the basis that the applicability of such studies to the present UK NHS context was likely to be too low to inform the guideline committee's decision making. In addition, studies not published in English were excluded. The remaining health economic studies were prioritised for inclusion based on their relative applicability and the study limitations. The hierarchies used to guide this prioritisation process are listed in Table 1 , which presents the review protocol. The categories for the assessment of applicability and methodological quality are illustrated in Table 2 , and the criteria used are listed in the NICE economic evaluation checklist available in Appendix H of the NICE Guidelines Manual (https ://www.nice.org. uk/proce ss/pmg20 /resou rces/appen dix-h-pdf-25497 10190 ) [60] . The main criteria for judging the applicability are related to the nature of the population, the intervention, the perspective, and the method used for measuring and valuing health outcomes. The criteria used for judging methodological quality include time horizon, source of efficacy estimates, source of baseline risks, source of unit costs and assessment of uncertainty.
Data from the included studies, including country, population, study design, intervention(s) and comparator, followup, costs and cost categories, outcomes and source of effectiveness evidence, incremental costs, incremental effects and conclusion regarding cost effectiveness, were extracted in standard evidence tables by one of the authors (DD). Where costs were reported in currencies other than UK Pounds Sterling (GBP), conversion was undertaken using the OECD purchasing power parity conversion rates for the corresponding cost year. Costs were not inflated.
Results
The database search retrieved 3124 records, of which 27 papers were considered for inclusion and assessed for applicability and methodological quality. This assessment resulted in the decision to include 13 studies, published in 14 papers [21, 25, 37, 43, 47, 49, [61] [62] [63] [64] [65] [66] [67] [68] . A table presenting the studies that were either excluded or selectively excluded, based on quality and applicability assessment, with the reasons for exclusion/selective exclusion is included in Online Resource 1. The study selection flow chart is presented in Fig. 1 .
The included studies were conducted in the UK (six studies) [37, 47, 49, 61, 62, 66, 68] , Spain (two studies) [25, 64] , The Netherlands (one study) [67] , Australia (one study) [21] , Italy (one study) [65] , and Canada (two studies) [43, 63] . Ten of these studies were cost-utility analyses (CUAs) [21, 25, 37, 47, 49, 61, 62, [65] [66] [67] , with health outcomes reported in terms of quality-adjusted life-years (QALYs), while two studies were cost-effectiveness analyses (CEAs) [43, 63] , and one study was a cost-benefit analysis (CBA) [64] . The interventions provided by the pharmacists were primarily medicines management services that covered the following areas: coronary heart disease (CHD), asthma care programme, diabetes mellitus, uncontrolled hypertension, cardiovascular disease, and elderly patients with polypharmacy, patients with adherence problems and patients recently discharged from hospital. All studies were assessed as partially applicable, except two studies that were assessed as directly applicable [49, 62] . The details of the included studies and their results are summarised in Tables 3 and 5 .
All studies except one [62] were also assessed as having potentially serious limitations. The rationale for the quality and applicability assessments are presented in Table 4 .
The studies were conducted at community pharmacy settings (nine studies) [21, 25, 47, 49, 62-65, 67, 68] , the patient's domicile/home (two studies) [61, 66] , or general practice surgeries/primary care clinics (two studies) [37, 43] . In 12 studies, the services were delivered by community pharmacists, while the remaining studies assessed the service provided by a clinical pharmacist, with and without a prescribing qualification. Of the nine studies conducted in the community pharmacy settings, six studies showed that All interventions will be compared with usual care as described by the study Objectives
To identify economic evaluations relevant to the review question Search criteria Studies must be of a relevant economic study design (cost-utility analysis, cost-effectiveness analysis, cost-benefit analysis, cost-consequences analysis, comparative cost analysis) Studies must not be a letter, editorial or commentary, or a review of economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered) Unpublished reports will not be considered unless submitted as part of a call for evidence Studies must be in English Review strategy Studies not meeting any of the search criteria above will be excluded. Studies published before 2005, abstract-only studies and studies from non-OECD countries or the US will also be excluded Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist that can be found in Appendix G of the NICE guidelines manual (2012) [60] Inclusion and Exclusion Criteria If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. An economic evidence table will be completed and will be included in the economic evidence profile If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If excluded, then an economic evidence table will not be completed and it will not be included in the economic evidence profile If a study is rated as 'Partially applicable', with 'Potentially serious limitations', or both, then there is discretion over whether it should be included Where There is Discretion The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the committee if required. The ultimate aim is to include studies that are helpful for decision making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation. The health economist will be guided by the following hierarchies. Setting: UK NHS (most applicable) OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden) OECD countries with predominantly private health insurance systems (for example, Switzerland) Studies set in non-OECD countries or in the US will have been excluded before being assessed for applicability and methodological limitations Economic study type: Cost-utility analysis (most applicable) Other type of full economic evaluation (cost-benefit analysis, cost-effectiveness analysis, cost-consequences analysis) Comparative cost analysis Non-comparative cost analyses, including cost-of-illness studies, will have been excluded before being assessed for applicability and methodological limitations Year of analysis: The more recent the study, the more applicable it will be Studies published in 2005 or later, but which depend on unit costs and resource data entirely, or predominantly from before 1999, will be rated as 'Not applicable' Studies published before 2005 will have been excluded before being assessed for applicability and methodological limitations enhanced-role community pharmacists at community pharmacies dominated usual care by reducing costs and improving health outcomes [25, [62] [63] [64] [65] 67] . Four of these studies were CUAs [25, 62, 65, 67] , one was a CEA [63] and one was a CBA [64] . Three CUA studies found that enhancedrole community pharmacists at community pharmacies were cost effective compared with usual care, with incremental cost-effectiveness ratios (ICERs) of £7350, £2121 and £10,000 per QALY gained, respectively [21, 47, 49, 68] .
The two studies assessing the cost effectiveness of enhanced-role community pharmacists' services provided at the patient's home were CUAs [61, 66] . One found that the community pharmacist intervention was not cost effective compared with usual care (ICER £54,454 per QALY gained) [66] , whereas the second study found that it was less effective but cost-saving compared with usual care, with a saving of £16,157 per QALY lost, which means that usual care is more cost effective at a cost-effectiveness threshold of £20,000 per QALY gained [61] .
Finally, two studies assessed the cost effectiveness of clinical pharmacist provision of services at a GP surgery [37, 43] . One study, a CEA conducted in Canada [43] , found that the pharmacist intervention was dominant, reducing costs (savings of £102) and improving health outcomes. The second study, conducted in the UK, found that the pharmacist intervention was cost effective compared with usual care (ICER £5567 per QALY gained) [37] . When the intervention was delivered by a prescribing pharmacist though, the ICER increased to £11,304 per QALY gained. However, the intervention remained below the £20,000 per QALY gained threshold when compared with usual care.
Discussion
Thirteen studies published in 14 papers were included in this review [21, 25, 37, 43, 47, 49, [61] [62] [63] [64] [65] [66] [67] [68] . Of these included studies, nine studies published in ten papers found that interventions provided by enhanced-role community pharmacists at community pharmacies either dominated usual care (by reducing costs and improving health outcomes) or were cost effective compared with usual care, using a threshold of £20,000 per QALY gained [21, 25, 47, 49, 62-65, 67, 68] . Community pharmacist interventions delivered at the patient's home were not found to be cost effective compared with usual care [61, 66] . Two studies examining pharmacist interventions delivered at GP surgeries either dominated or were cost effective compared with usual care [37, 43] .
The included studies showed that there is strong economic evidence to support the cost effectiveness of enhanced-role community pharmacists' interventions delivered at community pharmacies. The interventions described in the studies covered conducting MURs and providing support for those starting on newly prescribed medicines (NMS). These interventions reflected the advanced services currently provided at community pharmacies in England, which have been established for some time, and the accumulated evidence strongly supports the continuation of their provision. Thus, it could be argued that enhancing the role of community pharmacists to allow for expansion in the provision of these services represents good value for money by improving health outcomes while being either cost saving or cost effective, with ICERs well below the cost-effectiveness threshold specified by NICE. It was also reassuring that the interventions assessed in these studies generally reflected practice in the target setting. This was particularly the case for four of the nine studies as they were UK studies [47, 49, 62, 68] , with one assessed as being directly applicable with minor limitations [49] . Although the interventions in some of the non-UK studies were slightly different to how services The economic evaluation checklists are available in Appendix H of the NICE Guidelines Manual (https ://www.nice.org.uk/proce ss/ pmg20 /resou rces/appen dix-h-pdf-25497 10190 ) NHS National Health Service, NICE National Institute for Health and Care Exellence Item Description Applicability An assessment of applicability of the study to this guideline, the current NHS situation and NICE decision making Directly applicable: the study meets all applicability criteria, or fails to meet one or more applicability criteria, but this is unlikely to change the conclusions about cost effectiveness Partially applicable: the study fails to meet one or more applicability criteria, which could change the conclusions about cost effectiveness. Not applicable: the study fails to meet one or more of the applicability criteria, which is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review Quality An assessment of the methodological quality of the study: Minor limitations: the study meets all quality criteria, or fails to meet one or more quality criteria, but this is unlikely to change the conclusions about cost effectiveness Potentially serious limitations: the study fails to meet one or more quality criteria, which could change the conclusions about cost effectiveness Very serious limitations: the study fails to meet one or more quality criteria, which is highly likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from the review are delivered in the UK, there was no heterogeneity in the results, with all showing that the interventions were cost effective. This supported our conclusion that these services are generally cost effective despite the fact that some differences might exist in how they are delivered. It has to be noted though that quality of life as an outcome was directly measured, using preference-based quality-of-life measures such as the EQ-5D, in a small number of the included trials. These showed that the magnitude of improvement was generally small and a significant difference between trial arms was seen in three of five studies that reported collecting these data [25, 64, 65] . However, the studies reflected cost effectiveness, both in the short and long term, as the follow-up time in the economic evaluations conducted alongside clinical studies ranged from 6 to 12 months [25, 47, 49, 64, 65, 68] , while the modelling studies had time horizons ranging from 1 year to a lifetime [21, 62, 63, 67] , which was also reassuring.
For community pharmacist interventions delivered at GP practices, the UK study showed that there was no difference between prescribing and non-prescribing pharmacists in terms of health outcomes [37] . As the cost of the intervention would be higher when delivered by a prescribing pharmacist, this meant that when the intervention was delivered by prescribing pharmacists, it was not cost effective compared with the intervention delivered by non-prescribing pharmacists. The higher costs of interventions delivered by prescribing pharmacists is partly a result of the cost of the prescribing qualification, but it has also been reported that prescribing pharmacists tend to have longer appointments with patients, which might contribute to the higher costs [70] . Thus, studies with longer follow-up might be required where these higher upfront costs can potentially be shown to be offset by improvement in outcomes or provision of the service to more patients [70] .
However, it was demonstrated that interventions provided by advanced-role pharmacists at GP practices were at least as effective as usual care. This could potentially have an additional positive impact on the workload of GPs by freeing up their time to focus on the more complex patients. NHS England's strategic plan for general practice (the GP Forward View) supported this conclusion [71] . The report outlined plans to provide an additional 1500 pharmacists to join the general practice workforce by 2020, acknowledging their role as a member of the general practice workforce and their expected positive impact on the workload of GPs. This has been further supported in the NHS long-term plan and is currently being implemented in the UK [9] . However, one finding worth noting is that the intervention was more cost effective when clinical pharmacists provided the interventions compared with when community pharmacists did, indicating that community pharmacists would need more training in terms of their clinical skills (for example, physical examination and history taking), and more time to integrate into the GP practice team in order to realise the benefit of their adoption of practice-based roles. It has to be noted though that there is no clear distinction between a clinical pharmacist and a community pharmacist. Historically, a community pharmacist has been based within a community pharmacy and a clinical pharmacist within a hospital ward; however, recently the distinction has become more blurred. Nonetheless, it is likely that these two roles will converge, even when located within the same setting, with the expectation that community pharmacists will concentrate on medication adherence and/or patient education, therefore supporting the role of the GP, whereas clinical pharmacists will have a greater clinical involvement with patients, therefore replacing the involvement of GPs in some situations. This has been acknowledged with the introduction of the Pharmacy Integration Fund, which aims to train community pharmacists to undertake advanced roles based in GP practices [72] . This included the creation of a new 'Practice Pharmacist' role, by which pharmacists from any practice background (hospital, community or primary care) could work at GP practices provided they have the necessary skills and competencies [73] . The fund, worth £20 million in 2016 and rising to a total of £300 million by 2020-2021, is intended to help pharmacists and their teams to be fully incorporated across NHS planning and service delivery. Given the favourable economic evidence, the initial investment to enhance pharmacists' skills to undertake these practice-based roles would be expected to show positive returns in the long term.
The two UK studies that looked at the provision of community pharmacist interventions at the patient's home had contradictory results in terms of costs and health outcomes, but had the same conclusion regarding cost effectiveness [61, 66] . One study showed that the intervention was ineffective (loss of 0.019 QALYs), despite increasing adherence by 10%. There were cost savings but these were insufficient to justify the QALYs lost [61] . The second study showed that the pharmacist intervention increased cost (£407 per patient) and had a relatively small increase in QALYs of 0.0075, which meant it was not cost effective, with an ICER of £54,454 per QALY [66] . However, the evidence was primarily focused on visits to the patients' homes and did not apply to pharmacists' interventions at residential care and/or nursing care homes, which were not within the scope of this review. Hence, it could be concluded that the provision of services at patients' homes should only be targeted at those who cannot attend pharmacy-or clinic-based consultations [21] Partially applicable Potentially serious limitations The analysis is from an Australian healthcare perspective and may not be applicable to the UK NHS perspective. The transition probabilities in the model are derived from a single RCT with a follow-up of just 6 months. Assumptions were made that the treatment effects would be maintained in the long term. The discount rate used was higher than the 3.5% in the NICE reference case, however a sensitivity analysis with undiscounted costs and QALYs was performed and the conclusion did not change. Quality of life was not measured using the EQ-5D Houle et al., 2012 [63] Partially applicable Potentially serious limitations The analysis is from a Canadian healthcare perspective and may not be applicable to the UK NHS perspective. QALYs are not estimated and the impacts on quality of life and mortality are not assessed. The model uses an intermediate outcome taken from an RCT to predict the impacts on myocardial infarctions, stroke and heart failure. These outcomes are not directly measured and there is therefore some uncertainty regarding modelling process. Nonetheless, the model is built on good data Jodar-Sanchez et al., 2015 [25] Partially applicable Potentially serious limitations Some uncertainty regarding the applicability of resource use and costs from Spain in 2014 to the current UK NHS perspective. The perspective used is that of the Spanish NHS. An RCT-based analysis, therefore, by definition, the evidence was based on one study and does not reflect all evidence in this area. The follow-up was 6 months, which is unlikely to capture all differences in costs and outcomes. No sensitivity analysis is presented RESPECT trial team 2010(a) [49] Directly applicable Minor limitations Some uncertainty regarding the applicability of resource use and costs from 2004 to 2005 to the current NHS context. An RCT-based analysis, therefore, by definition, the evidence was based on one study and does not reflect all evidence in this area. Follow-up was for 12 months, which might not be long enough to capture all the differences in costs and outcomes Vegter et al., 2014 [67] Partially applicable Potentially serious limitations The source of the intervention effectiveness estimate is from a single, non-randomised study, therefore, by definition, does not reflect all evidence in this area.
The base-case analysis assumes that intervention effectiveness persists over the lifetime time horizon. It is not clear if the unit costs used are from national or local sources, which might limit the generalisability of the results CPMMPE Community Pharmacy Medicines Management Project Evaluation, NHS National Health Service, NICE National Institute for Health and Care Services, PSS Personal Social Services, QALYs quality-adjusted life-years, RCT randomised controlled trial Partially applicable Potentially serious limitations The study does not measure health benefits in QALYs and no baseline EQ-5D was measured in the before intervention group, therefore QALY calculations would rely on assumptions based on the baseline of the after intervention group. The analysis was based on a single before and after evaluation of the service change and therefore may be subject to confounding. A single patient group is used to assess the effects both before and after, and this therefore increases the risk of bias further Pacini et al., 2007 [66] Partially applicable Potentially serious limitations Some uncertainty regarding the applicability of resource use and costs from the year 2000 to the current NHS context. An RCT-based analysis, therefore, by definition, the evidence was based on one study and does not reflect all evidence in this area. Followup was for 6 months, which might not be long enough to capture all the differences in costs and outcomes Simpson et al., 2015 [43] Partially applicable Potentially serious limitations Costs in this study may not be applicable to the UK NHS perspective, and health benefits are not measured in QALYs. An RCT-based analysis, therefore, by definition, the evidence was based on one study and does not reflect all evidence in this area. Followup was for 12 months, which might not be long enough to capture all the differences in costs and outcomes Neilson et al., 2015 [37] Partially applicable Potentially serious limitations The population is a specific population that may not fully represent people at risk of an acute medical emergency. The analysis was based on a single RCT with only a 6-month follow-up period. Quality of life was not measured using the EQ-5D. A probabilistic sensitivity analysis was not performed and may well change the conclusion of the analysis due to the small differences in the quality-of-life scores Elliott et al., 2017 [62] Directly applicable Potentially serious limitations Some uncertainty regarding the applicability of resource use and unit costs from 2014 to the current NHS context. The analysis was based on a single RCT with outcome reported at 10 weeks. The link between the intermediate outcome (adherence to medication and final outcomes, including quality of life) was based on weak epidemiological data and, in some cases, on assumptions. Quality of life was not measured using the EQ-5D for the asthma model Malet-Larrea et al., 2017 [64] Partially applicable Potentially serious limitations Some uncertainty regarding the applicability of resource use and costs from the Spanish health care system in 2014 to the current UK NHS context. The analysis was based on a single RCT (the CONSIgue trial) undertaken in Spain. The time horizon for the analysis was limited to 6 months. A probabilistic sensitivity analysis was not performed Manfrin et al., 2017 [65] Partially applicable Potentially serious limitations Some uncertainty regarding the applicability of resource use and costs from the Italian health care system in 2015 to the current UK NHS context. The cost-effectiveness threshold used to calculate the probability being cost effective is different from that used in the UK NHS. The analysis was based on a single RCT. The cost and utility data were based on published studies rather than being collected alongside the trial. The follow-up was limited to 9 months from baseline Net monetary benefit = £378 Benefit:cost ratio = 3.33:1 Two scenarios were reported using the lower and upper limits of the estimated range of the monetary value for a QALY. Sensitivity analyses were also undertaken where the health benefits were added, a fee for service was added, number of patients using the service and the length of service provision were changed. Every case considered in the sensitivity analyses provided positive net benefit for the intervention due to health limitations (e.g. reduced mobility) as the benefit gained is unlikely to justify the higher costs associated with these [74] . This systematic literature review of published economic evaluations has been undertaken in accordance with the NICE guideline development manual [75] to ensure that the included studies represent the best evidence to inform recommendations for the English NHS setting. We excluded studies from non-OECD countries and also those from the US due to the clear differences between these health care systems and the NHS in England. Patients and clinicians' input were regularly sought during the development of the review questions and its protocol. Updating the search in March 2018 also ensured that the paper presents the most up-to-date review of economic evidence and that studies continue to show consistent results.
Although our review included only 13 studies, and for some settings our conclusions are based on only two studies, the applicability of the studies enabled the guideline committee to draw robust conclusions that are likely to be generalisable to other universal coverage, centrally-funded health systems. It enabled the committee to make practice recommendations for commissioners in England, specifying where pharmacy services represent good use of the limited health care resources. Similar to previously published reviews, we identified a need for better quality economic evaluations of pharmacy services, particularly those delivered at patients' homes and physicians' offices [74, 76, 77] . This is clearly a result of the more recent introduction of pharmacy services in these settings. The rollout of advanced pharmacy services in the UK can provide an important opportunity for parallel high-quality economic evaluations to be undertaken to address this gap in the current evidence [76, 78] .
Conclusions
Advanced interventions delivered at community pharmacies for adults with or at risk of developing acute illness and medical emergencies appear to be cost effective. Conclusions regarding the cost effectiveness of interventions delivered at general practice surgeries/in a primary care setting vary, with some evidence available showing better cost effectiveness when the intervention is delivered by clinically trained pharmacists. Pharmacist interventions delivered in the patients' own homes are unlikely to be cost effective, on average. These services should be commissioned on an individual basis, taking patient needs into account. More good-quality economic evaluations of these important services would be helpful to ensure the robustness of these conclusions and, preferably, identify Costs reported in currencies other than pound sterling are converted using OECD purchasing power parity conversion rates for the same year (source: https ://data.oecd.org/conve rsion /purch asing -power -parit ies-ppp.htm) the service configuration that is likely to lead to optimal outcomes.
